CCND1 G870A polymorphism contributes to breast cancer susceptibility: A meta-analysis

Breast Cancer Research and Treatment

Volumn 116, Issue 3, 2009, Pages 571-575

  Lu, Cheng ^a,b   Dong, Jing ^b   Ma, Hongxia ^b   Jin, Guangfu ^b   Hu, Zhibin ^b   Peng, Yuzhu ^a   Guo, Xirong ^a   Wang, Xinru ^b   Shen, Hongbing ^b  

^a WOMEN S HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Breast Cancer Meta analysis; CCND1; Polymorphism

Indexed keywords

ADENOSINE; CYCLIN D1; GUANOSINE; CCND1 PROTEIN, HUMAN;

ARTICLE; ASIAN; BREAST CANCER; BREAST CARCINOGENESIS; CANCER RISK; CANCER SUSCEPTIBILITY; CAUCASIAN; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; PRIORITY JOURNAL; RACE; BREAST TUMOR; CASE CONTROL STUDY; FEMALE; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; META ANALYSIS; PROGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

BREAST NEOPLASMS; CASE-CONTROL STUDIES; CYCLIN D1; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS;

EID: 70349561095     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-008-0195-y     Document Type: Article

References (32)

1. Ormandy CJ, Musgrove EA, Hui R, Daly RJ, Sutherland RL (2003) Cyclin D1, EMS1 and 11q13 amplification in breast cancer. Breast Cancer Res Treat 78(3):323-335. doi:10.1023/A:1023033708204
2. Malumbres M, Barbacid M (2001) To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 1(3):222-231. doi: 10.1038/35106065
3. Cook SJ, Balmanno K, Garner A, Millar T, Taverner C, Todd D (2000) Regulation of cell cycle re-entry by growth, survival and stress signalling pathways. Biochem Soc Trans 28(2):233-240
4. Sherr CJ (1996) Cancer cell cycles. Science 274(5293):1672-1677. doi: 10.1126/science.274.5293.1672
5. Zhou P, Jiang W, Weghorst CM, Weinstein IB (1996) Overexpression of cyclin D1 enhances gene amplification. Cancer Res 56(1):36-39
6. Yang L, Parkin DM, Ferlay J, Li L, Chen Y (2005) Estimates of cancer incidence in China for 2000 and projections for 2005. Cancer Epidemiol Biomarkers Prev 14(1):243-250
7. Barnes DM, Gillett CE (1998) Cyclin D1 in breast cancer. Breast Cancer Res Treat 52(1-3):1-15. doi:10.1023/A:1006103831990
8. Steeg PS, Zhou Q (1998) Cyclins and breast cancer. Breast Cancer Res Treat 52(1-3):17-28. doi:10.1023/A:1006102916060
9. Hosokawa Y, Arnold A (1998) Mechanism of cyclin D1 (CCND1, PRAD1) overexpression in human cancer cells: analysis of allele-specific expression. Genes Chromosomes Cancer 22(1):66-71. doi:10.1002/(SICI)1098-2264(199805)22: 1<66:: AID-GCC9<3.0.CO;2-5
10. Knudsen KE, Diehl JA, Haiman CA, Knudsen ES (2006) Cyclin D1: polymorphism, aberrant splicing and cancer risk. Oncogene 25(11):1620-1628. doi:10.1038/sj.onc.1209371
11. Kandel R, Zhu XL, Li SQ, Rohan T (2001) Cyclin D1 protein overexpression and gene amplification in benign breast tissue and breast cancer risk. Eur J Cancer Prev 10(1):43-51. doi:10.1097/00008469-200102000-00005
12. Sutherland RL, Musgrove EA (2002) Cyclin D1 and mammary carcinoma: new insights from transgenic mouse models. Breast Cancer Res 4(1):14-17. doi:10.1186/bcr411
13. Betticher DC, Thatcher N, Altermatt HJ, Hoban P, Ryder WD, Heighway J (1995) Alternate splicing produces a novel cyclin D1 transcript. Oncogene 11(5):1005-1011
14. Solomon DA, Wang Y, Fox SR, Lambeck TC, Giesting S, Lan Z et al (2003) Cyclin D1 splice variants. Differential effects on localization, RB phosphorylation, and cellular transformation. J Biol Chem 278(32):30339-30347. Erratum in: J Biol Chem 2004 Jul 16; 279. 29:30914. doi:10.1074/jbc.M303969200
15. Sawa H, Ohshima TA, Ukita H, Murakami H, Chiba Y, Kamada H et al (1998) Alternatively spliced forms of cyclin D1 modulate entry into the cell cycle in an inverse manner. Oncogene 16(13):1701-1712. doi: 10.1038/sj.onc.1201691
16. Grieu F, Malaney S, Ward R, Joseph D, Iacopetta B (2003) Lack of association between CCND1 G870A polymorphism and the risk of breast and colorectal cancers. Anticancer Res 23(5b):4257-4259
17. Shu XO, Moore DB, Cai Q, Cheng J, Wen W, Pierce L et al (2005) Association of cyclin D1 genotype with breast cancer risk and survival. Cancer Epidemiol Biomarkers Prev 14(1):91-97
18. Ceschi M, Sun CL, Van Den Berg D, Koh WP, Yu MC, Probst-Hensch N (2005) The effect of cyclin D1 (CCND1) G870A- polymorphism on breast cancer risk is modified by oxidative stress among Chinese women in Singapore. Carcinogenesis 26(8):1457-1464. doi:10.1093/carcin/bgi093
19. Yu CP, Yu JC, Sun CA, Tzao C, Ho JY, Yen AM (2008) Tumor susceptibility and prognosis of breast cancer associated with the G870A polymorphism of CCND1. Breast Cancer Res Treat 107(1):95-102. doi:10.1007/s10549-007-9522-y
20. Försti A, Angelini S, Festa F, Sanyal S, Zhang Z, Grzybowska E et al (2004) Single nucleotide polymorphisms in breast cancer. Oncol Rep 11(4):917-922
21. Krippl P, Langsenlehner U, Renner W, Yazdani-Biuki B, Wolf G, Wascher TC et al (2003) The 870G>A polymorphism of the cyclin D1 gene is not associated with breast cancer. Breast Cancer Res Treat 82(3):165-168. doi:10.1023/B:BREA. 0000004372.20461.33
22. Onay UV, Aaltonen K, Briollais L, Knight JA, Pabalan N, Kilpivaara O et al (2008) Combined effect of CCND1 and COMT polymorphisms and increased breast cancer risk. BMC Cancer 8:6. doi:10.1186/1471-2407-8-6
23. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629-634
24. Radu A, Neubauer V, Akagi T, Hanafusa H, Georgescu MM (2003) PTEN induces cell cycle arrest by decreasing the level and nuclear localization of cyclin D1. Mol Cell Biol 23(17):6139-6149. doi: 10.1128/MCB.23.17.6139-6149.2003
25. Alle KM, Henshall SM, Field AS, Sutherland RL (1998) Cyclin D1 protein is overexpressed in hyperplasia and intraductal carcinoma of the breast. Clin Cancer Res 4(4):847-854
26. Lu F, Gladden AB, Diehl JA (2003) An alternatively spliced cyclin D1 isoform, cyclin D1b, is a nuclear oncogene. Cancer Res 63(21):7056-7061
27. Wang L, Habuchi T, Takahashi T, Mitsumori K, Kamoto T, Kakehi Y et al (2002) Cyclin D1 gene polymorphism is associated with an increased risk of urinary bladder cancer. Carcinogenesis 23(2):257-264. doi:10.1093/carcin/23.2. 257
28. Zhang J, Li Y, Wang R, Wen D, Sarbia M, Kuang G et al (2003) Association of cyclin D1 (G870A) polymorphism with susceptibility to esophageal and gastric cardiac carcinoma in a northern Chinese population. Int J Cancer 105(2):281-284. doi:10.1002/ijc.11067
29. Wang L, Habuchi T, Mitsumori K, Li Z, Kamoto T, Kinoshita H et al (2003) Increased risk of prostate cancer associated with AA genotype of cyclin D1 gene A870G polymorphism. Int J Cancer 103(1):116-120. doi:10.1002/ijc.10793
30. Zheng Y, Shen H, Sturgis EM, Wang LE, Eicher SA, Strom SS et al (2001) Cyclin D1 polymorphism and risk for squamous cell carcinoma of the head and neck: a case-control study. Carcinogenesis 22(8):1195-1199. doi:10.1093/carcin/ 22.8.1195
31. Tan XL, Nieters A, Kropp S, Hoffmeister M, Brenner H, Chang-Claude J (2008) The association of cyclin D1 G870A and E-cadherin C-160A polymorphisms with the risk of colorectal cancer in a case control study and meta-analysis. Int J Cancer 122(11):2573-2580. doi:10.1002/ijc.23363
32. Lewis RC, Bostick RM, Xie D, Deng Z, Wargovich MJ, Fina MF et al (2003) Polymorphism of the cyclin D1 gene, CCND1, and risk for incident sporadic colorectal adenomas. Cancer Res 63(23):8549-8553